Work

Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?

Year: 2018

Type: article

Abstract: Immune checkpoint inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune checkpoint therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizumab clearance and poor response, highlighting the immense therapeutic challenge posed by cancer cachexia. See related article by Turner et al., p. 5841

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-18-1847

Authors: Christopher C. Coss, Steven K. Clinton, Mitch A. Phelps

Institution: The Ohio State University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute